Key Takeaways:
Immix Biopharma Inc. closed its underwritten public offering of 16,778,524 common shares for gross proceeds of approximately $150 million to fund clinical trials.
The financing included leading U.S. biotechnology institutional investors and mutual funds, the company said in a statement on May 22.
The offering was priced at $8.94 per share, generating net proceeds of about $140.65 million after underwriting discounts and other expenses. The new issuance increases the total shares outstanding to approximately 69.8 million. Morgan Stanley and BofA Securities acted as book-running managers for the deal.
The capital raise significantly strengthens ImmixBio’s balance sheet, which showed $90.6 million in cash as of March 31, extending its runway to fund development of its lead CAR-T therapy candidate, NXC-201, for AL Amyloidosis.
The sale was conducted under a “shelf” registration statement on Form S-3 that was declared effective by the U.S. Securities and Exchange Commission on January 22, 2026. This allows the company to raise up to $750 million over time.
The offering, which follows a $100 million financing in December 2025, provides ImmixBio with capital to advance its late-stage clinical trials. Investors will now watch for key data readouts from the NEXICART-2 study for the company's lead drug candidate.
This article is for informational purposes only and does not constitute investment advice.
